Abstract:As a crucial transcription factor, sex-determining region Y box 12 (SOX12) is closely related with tumorigenesis and malignant transformation in various malignant tumor types. To date, the specific function of SOX12 in esophageal squamous cell carcinoma (ESCC) has remained largely elusive and requires further investigation. The present study aimed to determine whether aberrant expression of SOX12 is associated with malignant development of ESCC. The expression level of SOX12 in ESCC cells and tissues was analyzed by RT-qPCR and western blotting. Short hairpin RNA (shRNA) targeting SOX12 was transfected into ESCC cells to knock down the expression of SOX12. Colony formation and Transwell assays were used to detect viability and mobility of ESCC cells. Signaling pathway-related proteins were assessed using western blot analysis and cellular immunofluorescence. Clinical prognosis data was analyzed by Kaplan-Meier and Cox logistic regression. The present results revealed that SOX12 was overexpressed in ESCC cells and tissues. Knockdown of the expression of SOX12 by shRNA inhibited the colony forming efficiency, migration and invasion capacities of ESCC cells in vitro. Recombinant protein of SOX12 could restore the aggressive phenotype of ESCC cells. Furthermore, knockdown of the expression of SOX12 inhibited the activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway by decreasing the expression of the JAK2/STAT3 signaling pathway. Recombinant protein of SOX12 could recover the activation of the JAK2/STAT3 signaling pathway. Analysis of the clinical data revealed that overexpression of SOX12 indicated shorter overall survival time (OS; P=0.0341) and disease-free survival time (DFS; P=0.04). Univariate and multivariate analysis revealed that overexpression of SOX12 was an independent factor for ESCC. In conclusion, SOX12 was revealed to serve a crucial function in sustaining the viability, as well as enhancing the motility of ESCC cells via activating the JAK2/STAT3 signaling pathway. Thus, SOX12 may potentially serve as a novel biomarker and candidate for the targeted treatment of ESCC.

Reciprocal Activation of HEY1 and NOTCH4 under SOX2 Control Promotes EMT in Head and Neck Squamous Cell Carcinoma

The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma

Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression

Interplay Between Notch 1 and Notch 3 Promotes EMT and Tumor Initiation in Squamous Cell Carcinoma

Silencing Sox2 Induced Mesenchymal-Epithelial Transition And Its Expression Predicts Liver And Lymph Node Metastasis Of Crc Patients

Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma

The Hippo Effector TAZ Promotes Cancer Stemness by Transcriptional Activation of SOX2 in Head Neck Squamous Cell Carcinoma

Reciprocal regulation of LINC00941 and SOX2 promotes progression of esophageal squamous cell carcinoma

A predominant enhancer co-amplified with the SOX2 oncogene is necessary and sufficient for its expression in squamous cancer

EHMT2 Suppresses ARRB1 Transcription and Activates the Hedgehog Signaling to Promote Malignant Phenotype and Stem Cell Property in Oral Squamous Cell Carcinoma

The impact of LncRNA-SOX2-OT/let-7c-3p/SKP2 Axis on head and neck squamous cell carcinoma progression: Insights from bioinformatics analysis and experimental validation

Sox2 Promotes Tumor Aggressiveness and Epithelial‑mesenchymal Transition in Tongue Squamous Cell Carcinoma.

AFF4 Promotes Tumorigenesis and Tumor-Initiation Capacity of Head and Neck Squamous Cell Carcinoma Cells by Regulating SOX2

FOXD1 promotes EMT and cell stemness of oral squamous cell carcinoma by transcriptional activation of SNAI2

FOXM1 Promotes Head and Neck Squamous Cell Carcinoma Via Activation of the Linc-ROR/LMO4/AKT/PI3K Axis.

HEY2 acting as a co-repressor with smad3 and smad4 interferes with the response of TGF-beta in hepatocellular carcinoma.

The Notch signaling pathway in head and neck squamous cell carcinoma: A meta-analysis.

SOX18 Meditates the Resistance of Bmi1-expressing Cells to Cetuximab in HNSCC

SRY-related high-mobility-group box 4: Crucial regulators of the EMT in cancer

SOX12 Contributes to the Activation of the JAK2/STAT3 Pathway and Malignant Transformation of Esophageal Squamous Cell Carcinoma

Reprogramming of the esophageal squamous carcinoma epigenome by SOX2 promotes ADAR1 dependence